share_log

Needham Reiterates Buy on Harmony Biosciences, Maintains $52 Price Target

Benzinga ·  Oct 2 18:24  · Ratings

Needham analyst Ami Fadia reiterates Harmony Biosciences (NASDAQ:HRMY) with a Buy and maintains $52 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment